



## Global Access Program

Providing innovative diagnostics solutions to those who need it most



### Universal access to quality healthcare and medical innovation remains a global challenge.

As a community we have an ambitious goal: to stop as many diseases as possible.

Roche continues to partner with national governments, local healthcare facilities, communities and international agencies to go beyond providing diagnostics tests.




The Roche Global Access Program provides access to diagnostics for HIV, hepatitis, tuberculosis and cervical cancer in high disease burden and qualified countries where reliable diagnostic solutions are needed most.



### Global Access Program Timeline


- 2014** Announced Global Access Program for HIV viral load testing
- 2016-2017** Expansion to include Early Infant Diagnosis and additional **cobas**® Systems family
- 2018** Launch of **cobas**® simplify sample collection and transportation and increase access to HIV monitoring testing
- 2019** Expansion of the Global Access Program to include access to diagnostics for tuberculosis, hepatitis, and cervical cancer
- 2021** Expansion of the Global Access Program to include molecular PCR diagnostic tests for COVID-19

### DISEASE PREVALENCE: DEATHS




### DISEASE ELIMINATION GOALS


#### HIV goals by 2030<sup>6</sup>




#### Hepatitis goals by 2030<sup>7</sup>




#### TB goals by 2030<sup>8</sup>



#### Cervical cancer goals by 2030<sup>9</sup>




#### COVID-19 Elimination Strategy<sup>11</sup>



### COUNTRIES WITH GLOBAL ACCESS PROGRAM

The program provides increased access to diagnostics at affordable pricing for qualifying organizations in 82 eligible countries with the highest disease burden.



### REFERENCES:

- <https://www.unaids.org/en> (accessed 31 May 2023)
- <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b> (accessed 31 May 2023)
- <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c> (accessed 31 May 2023)
- <https://www.who.int/news-room/fact-sheets/detail/tuberculosis> (accessed 31 May 2023)
- [https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-\(hpv\)-and-cervical-cancer](https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer) (accessed 31 May 2023)
- Understanding Fast-Track. Accelerating Action to end the AIDS epidemic by 2030. [https://www.unaids.org/sites/default/files/media\\_asset/201506\\_JC2743\\_Understanding\\_FastTrack\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf) (Accessed 29 March 2021)
- <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=AC1645C173756FB7A161689347064065?sequence=1> (accessed 31 May 2023)
- The End TB Strategy 2015. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015.19
- [https://cdn.who.int/media/docs/default-source/cervical-cancer/230519-ccai-brochure.pdf?sfvrsn=8f15a050\\_58download=true](https://cdn.who.int/media/docs/default-source/cervical-cancer/230519-ccai-brochure.pdf?sfvrsn=8f15a050_58download=true) (accessed 31 May 2023)
- <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality> (Accessed 31 May 2023)
- Baker MG, Wilson N, Angleymer A. Successful Elimination of Covid-19 Transmission in New Zealand. N Engl J Med 2020;383:e56. 10.1056/NEJMc2025203

Roche Molecular Systems  
4300 Hacienda Drive  
Pleasanton, CA 94588 USA

<https://go.roche.com/Global-Access-Program>